These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31475931)

  • 1. Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.
    Anastasilakis AD; Polyzos SA; Makras P; Rauner M; Sonnleitner L; Hawa G; Tsourdi E; Yavropoulou MP; Missbichler A; Terpos E
    J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):253-257. PubMed ID: 31475931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriparatide and denosumab combination therapy and skeletal metabolism.
    Idolazzi L; Rossini M; Viapiana O; Braga V; Fassio A; Benini C; Kunnathully V; Adami S; Gatti D
    Osteoporos Int; 2016 Nov; 27(11):3301-3307. PubMed ID: 27250971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
    [No Abstract]   [Full Text] [Related]  

  • 5. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between P1NP and bone strength in postmenopausal women treated with teriparatide.
    Chen FP; Fu TS; Lin YC; Sung CM; Huang MH; Lin YJ
    Taiwan J Obstet Gynecol; 2022 Jan; 61(1):91-95. PubMed ID: 35181054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
    Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
    Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
    Anastasilakis AD; Makras P; Pikilidou M; Tournis S; Makris K; Bisbinas I; Tsave O; Yovos JG; Yavropoulou MP
    J Clin Endocrinol Metab; 2018 Mar; 103(3):1206-1213. PubMed ID: 29309589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Sakellariou G; Savvidis M; Papatheodorou A; Kokkoris P; Terpos E
    Expert Opin Ther Targets; 2015 Mar; 19(3):299-306. PubMed ID: 25395071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P; Savvidis M; Mantzoros CS
    J Bone Miner Res; 2024 Sep; 39(9):1306-1314. PubMed ID: 38976019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.
    Tsai JN; Lee H; David NL; Eastell R; Leder BZ
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):767-775. PubMed ID: 31447409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.
    Cosman F; McMahon D; Dempster D; Nieves JW
    J Bone Miner Res; 2020 Feb; 35(2):219-225. PubMed ID: 31419313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.